Computational Approaches That Predict Metabolic Intermediate Complex Formation with CYP3A4 (+b5)
暂无分享,去创建一个
Sean Ekins | Lang Li | S. Ekins | Lang Li | S. Hall | David R. Jones | David R Jones | Stephen D Hall | S. Hall
[1] C. Ernest,et al. Mechanism-Based Inactivation of CYP3A by HIV Protease Inhibitors , 2005, Journal of Pharmacology and Experimental Therapeutics.
[2] F. Lombardo,et al. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. , 2001, Advanced drug delivery reviews.
[3] S. Dworetzky,et al. Fluorine substitution can block CYP3A4 metabolism-dependent inhibition: identification of (S)-N-[1-(4-fluoro-3- morpholin-4-ylphenyl)ethyl]-3- (4-fluorophenyl)acrylamide as an orally bioavailable KCNQ2 opener devoid of CYP3A4 metabolism-dependent inhibition. , 2003, Journal of medicinal chemistry.
[4] C. Hansch,et al. Quantitative structure-activity relationships of cytochrome P-450. , 1993, Drug metabolism reviews.
[5] Mark T. D. Cronin,et al. Structure-Based Classification of Antibacterial Activity , 2002, J. Chem. Inf. Comput. Sci..
[6] Sean Ekins,et al. Generation and validation of rapid computational filters for cyp2d6 and cyp3a4. , 2003, Drug metabolism and disposition: the biological fate of chemicals.
[7] P. Chatterjee,et al. Human cytochrome p450 inhibition and metabolic-intermediate complex formation by goldenseal extract and its methylenedioxyphenyl components. , 2003, Drug metabolism and disposition: the biological fate of chemicals.
[8] B. Ring,et al. Comparative metabolic capabilities of CYP3A4, CYP3A5, and CYP3A7. , 2002, Drug metabolism and disposition: the biological fate of chemicals.
[9] Sean Ekins,et al. Development of Computational Models for Enzymes, Transporters, Channels, and Receptors Relevant to ADME/Tox , 2004 .
[10] N. Vermeulen,et al. A three-dimensional protein model for human cytochrome P450 2D6 based on the crystal structures of P450 101, P450 102, and P450 108. , 1996, Chemical research in toxicology.
[11] S. Hall,et al. Prediction of cytochrome P450 3A inhibition by verapamil enantiomers and their metabolites. , 2004, Drug metabolism and disposition: the biological fate of chemicals.
[12] Sean Ekins,et al. In vitro and pharmacophore insights into CYP3A enzymes. , 2003, Trends in pharmacological sciences.
[13] L. Pershing,et al. Cytochrome P-450 metabolic-intermediate complex formation and induction by macrolide antibiotics; a new class of agents. , 1982, Xenobiotica; the fate of foreign compounds in biological systems.
[14] Chris de Graaf,et al. Cytochrome p450 in silico: an integrative modeling approach. , 2005, Journal of medicinal chemistry.
[15] Sean Ekins,et al. Optimizing Higher Throughput Methods to Assess Drug-Drug Interactions for CYP1A2, CYP2C9, CYP2C19, CYP2D6, rCYP2D6, and CYP3A4 In Vitro Using a Single Point IC50 , 2002, Journal of biomolecular screening.
[16] Sean Ekins,et al. Pharmacophore modeling of cytochromes P450. , 2002, Advanced drug delivery reviews.
[17] H. Yamazaki,et al. Comparative studies of in vitro inhibition of cytochrome P450 3A4-dependent testosterone 6beta-hydroxylation by roxithromycin and its metabolites, troleandomycin, and erythromycin. , 1998, Drug metabolism and disposition: the biological fate of chemicals.
[18] M. Franklin. Inhibition of mixed-function oxidations by substrates forming reduced cytochrome P-450 metabolic-intermediate complexes , 1977 .
[19] S. Stanley Young,et al. Automated Pharmacophore Identification for Large Chemical Data Sets. , 1999 .
[20] H. Suzuki,et al. Studies on the cytochrome P450 (CYP)-mediated metabolic properties of miocamycin: evaluation of the possibility of a metabolic intermediate complex formation with CYP, and identification of the human CYP isoforms. , 2000, Drug metabolism and disposition: the biological fate of chemicals.
[21] S. Ekins,et al. Pharmacophore and three-dimensional quantitative structure activity relationship methods for modeling cytochrome p450 active sites. , 2001, Drug metabolism and disposition: the biological fate of chemicals.
[22] A. Alex,et al. Novel approach to predicting P450-mediated drug metabolism: development of a combined protein and pharmacophore model for CYP2D6. , 1999, Journal of medicinal chemistry.
[23] D. Hawkins,et al. Analysis of a Large Structure‐Activity Data Set Using Recursive Partitioning , 1997 .
[24] D. Jones,et al. Diltiazem inhibition of cytochrome P-450 3A activity is due to metabolite intermediate complex formation. , 1999, The Journal of pharmacology and experimental therapeutics.
[25] T. Sjögren,et al. Structural basis for ligand promiscuity in cytochrome P450 3A4 , 2006, Proceedings of the National Academy of Sciences.
[26] A. Alex,et al. A novel approach to predicting P450 mediated drug metabolism. CYP2D6 catalyzed N-dealkylation reactions and qualitative metabolite predictions using a combined protein and pharmacophore model for CYP2D6. , 1999, Journal of medicinal chemistry.
[27] P. Watkins,et al. THE HUMAN CYP3A SUBFAMILY: PRACTICAL CONSIDERATIONS* , 2000, Drug metabolism reviews.
[28] Xin Chen,et al. Automated Pharmacophore Identification for Large Chemical Data Sets1 , 1999, J. Chem. Inf. Comput. Sci..
[29] E. Fuse,et al. Effects of olopatadine, a new antiallergic agent, on human liver microsomal cytochrome P450 activities. , 2002, Drug metabolism and disposition: the biological fate of chemicals.
[30] S. Grimm,et al. Reversible and irreversible inhibition of CYP3A enzymes by tamoxifen and metabolites , 2002, Xenobiotica; the fate of foreign compounds in biological systems.
[31] R. Silverman. Mechanism-based enzyme inactivation : chemistry and enzymology , 1988 .
[32] R. J. Riley,et al. Development of a Generalized, Quantitative Physicochemical Model of CYP3A4 Inhibition for Use in Early Drug Discovery , 2001, Pharmaceutical Research.
[33] S. Ekins,et al. Present and future in vitro approaches for drug metabolism. , 2000, Journal of pharmacological and toxicological methods.
[34] S. Ekins,et al. Three-dimensional-quantitative structure activity relationship analysis of cytochrome P-450 3A4 substrates. , 1999, The Journal of pharmacology and experimental therapeutics.
[35] Osman F. Güner,et al. Pharmacophore perception, development, and use in drug design , 2000 .
[36] Sean Ekins,et al. QUANTITATIVE STRUCTURE-METABOLISM RELATIONSHIP MODELING OF METABOLIC N-DEALKYLATION REACTION RATES , 2004, Drug Metabolism and Disposition.
[37] S D Hall,et al. An in vitro model for predicting in vivo inhibition of cytochrome P450 3A4 by metabolic intermediate complex formation. , 2000, Drug metabolism and disposition: the biological fate of chemicals.
[38] Christophe G. Lambert,et al. Mixture deconvolution and analysis of Ames mutagenicity data , 2002 .
[39] David W. Hosmer,et al. Applied Logistic Regression , 1991 .
[40] D. Stresser,et al. Fluorometric screening for metabolism-based drug--drug interactions. , 2000, Journal of pharmacological and toxicological methods.
[41] Jeffrey P. Jones,et al. Three-dimensional quantitative structure-activity relationship for inhibitors of cytochrome P4502C9. , 1996, Drug metabolism and disposition: the biological fate of chemicals.
[42] S. O. Kim,et al. Characterization of the selectivity and mechanism of cytochrome P450 inhibition by dimethyl-4,4'-dimethoxy-5,6,5',6'-dimethylenedioxybiphenyl-2,2'-dicarboxylate. , 2001, Drug metabolism and disposition: the biological fate of chemicals.
[43] Xin Chen,et al. Recursive Partitioning Analysis of a Large Structure-Activity Data Set Using Three-Dimensional Descriptors1 , 1998, J. Chem. Inf. Comput. Sci..